Image de couverture de livre

Epidemiology of Fontan‐associated liver disease in Japan: Results from a nationwide survey in 2021

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Satoko Ohfuji, Atsushi Tanaka, Tomomi Kogiso, Tatsuya Kanto
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Hepatology Research
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Evaluation of diagnostic criteria for mild‐to‐advanced stages of Fontan‐associated liver disease: A nationwide epidemiological survey in Japan
par: Tomomi Kogiso, et autres
Publié: (2024)

Real‐world trends in acute viral hepatitis in Japan: A nationwide questionnaire‐based survey
par: Kazuya Okushin, et autres
Publié: (2024)

Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan
par: Yasue Takeuchi, et autres
Publié: (2024)

Etiological changes of liver cirrhosis and hepatocellular carcinoma‐complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021
par: Hirayuki Enomoto, et autres
Publié: (2024)

What we know and need to know about Fontan‐associated liver disease
par: Kunimaro Furuta
Publié: (2024)

Extrahepatic Events in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and the Impact of Genetics and Alcohol Intake
par: Tomomi Kogiso, et autres
Publié: (2025)

Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10‐year follow‐up period
par: Kazuma Mori, et autres
Publié: (2024)

Association of liver fibrosis progression with non–liver‐related mortality in metabolic dysfunction‐associated steatotic liver disease
par: Toshifumi Tada, et autres
Publié: (2025)

Metabolic dysfunction‐associated steatotic liver disease is a risk factor for gallstones: A multicenter cohort study
par: Tomonori Cho, et autres
Publié: (2025)

Natural history and clinical features of hepatitis C virus infection during childhood: A nationwide, observational survey in Japan
par: Satoshi Nakano, et autres
Publié: (2024)

Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
par: Nobuharu Tamaki, et autres
Publié: (2024)

Prognostic performance of a two‐step method using the Fibro‐Scope system for metabolic dysfunction‐associated steatotic liver disease
par: Yuya Seko, et autres
Publié: (2024)

Clinical Characteristics and Long‐Term Prognosis of Primary Biliary Cholangitis in Japan: Results of the 2nd‐Generation Nationwide Survey
par: Yuki Kugiyama, et autres
Publié: (2025)

Impact of metabolic dysfunction‐associated fatty liver disease on the incidence of Helicobacter pylori‐negative gastric cancer
par: Tomoyuki Nakane, et autres
Publié: (2024)

Safety and effectiveness of SARS‐CoV‐2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire‐based, cross‐sectional study
par: Ayaka Tanifuji, et autres
Publié: (2024)

Metabolic dysfunction‐associated fatty liver disease and risks of incident coronary artery disease and cerebrovascular disease: LIFE Study
par: Yurina Akeno, et autres
Publié: (2025)

Treatment of liver cirrhosis in the era of steatotic liver disease
par: Masahito Shimizu
Publié: (2024)

Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease
par: Akihito Shiomi, et autres
Publié: (2024)

Associations of serum carotenoids with cardiovascular disease mortality among patients with metabolic dysfunction‐associated steatotic liver disease
par: Qian‐Qian Wang, et autres
Publié: (2025)

Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan
par: Masako Shomura, et autres
Publié: (2024)

Distribution of Fibrosis‐4 index and vibration‐controlled transient elastography‐derived liver stiffness measurement for patients with metabolic dysfunction‐associated steatotic liver disease in health check‐up
par: Yuji Ogawa, et autres
Publié: (2024)

Hepatic Mac2‐BP expression depends on liver fibrosis and inflammation due to fat accumulation in patients with metabolic dysfunction‐associated steatotic liver disease
par: Haruki Uojima, et autres
Publié: (2024)

Validation study of age‐independent fibrosis score (Fibrosis‐3 index) in patients with metabolic dysfunction‐associated steatotic liver disease
par: Kazuhiro Nouso, et autres
Publié: (2024)

The role of the nervous system in liver diseases
par: Boris Mravec, et autres
Publié: (2024)

Diagnostic guide for immune checkpoint inhibitor‐induced liver injury
par: Takanori Ito, et autres
Publié: (2024)

Comparison of hepatitis B virus genotype B and C patients in Japan in terms of family history and maternal age at birth
par: Kosuke Sato, et autres
Publié: (2025)

Brief intervention for chronic liver disease patients with alcohol use disorder in a hepatology outpatient unit: Effects and limitations
par: Nagisa Hara, et autres
Publié: (2024)

Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction‐associated steatotic liver disease
par: Masahito Nakano, et autres
Publié: (2024)

RECAM‐J 2023—Validation and development of the Japanese version of RECAM for the diagnosis of drug‐induced liver injury
par: Atsushi Tanaka, et autres
Publié: (2024)

Comparison between Japan and Korea in liver transplantation: Focusing on a higher deceased donation rate in Korea
par: Soo Ryang Kim, et autres
Publié: (2025)

Aspartate aminotransferase‐to‐platelet ratio index outperforms Fibrosis‐4 in 2843 Korean patients with metabolic dysfunction‐associated steatotic liver disease
par: Se Young Jang, et autres
Publié: (2024)

Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan
par: Yutaka Handa, et autres
Publié: (2026)

Imaging‐Based Surveillance of Gastroesophageal Varices in Fontan‐Associated Liver Disease: Toward a Noninvasive Strategy
par: Tadashi Namisaki, et autres
Publié: (2025)

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients
par: Nobuharu Tamaki, et autres
Publié: (2026)

Outcomes of immune checkpoint inhibitor‐induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team
par: Takanori Ito, et autres
Publié: (2024)

Grip strength is a strong indicator of osteoporosis in both women and men with chronic liver disease
par: Tatsuki Ichikawa, et autres
Publié: (2025)

Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early‐Stage Viral Disease
par: Kazuya Kariyama, et autres
Publié: (2025)

Surgical Resections for Hepatocellular Carcinomas Arising From Fontan‐Associated Liver Disease; Open, Laparoscopic and Robotic Hepatectomies
par: Takashi Motomura, et autres
Publié: (2026)

Efficacy of steroid therapy for improving native liver survival after pediatric acute liver failure with immune activation
par: Hiroshi Oue, et autres
Publié: (2024)

Impact of the revised Japanese indication criteria for deceased donor liver transplantation on liver cirrhotic patients of Child–Pugh classification B with hepatocellular carcinoma
par: Akihiro Seki, et autres
Publié: (2025)